Marius Pharmaceuticals Expands Access of KYZATREX™ (testosterone undecanoate) to Department of Veterans Affairs (VA), Pledging Support for Proper Hormonal Balance Among Military Personnel
19 sept. 2023 09h30 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, is proud to announce the...
Marius Pharmaceuticals Partners with Smartway to Design and Manage the global Early Access Program for KYZATREX™ (testosterone undecanoate)
10 août 2023 09h30 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals (Marius) and Smartway Pharmaceuticals (Smartway) are pleased to announce their strategic partnership, aimed at addressing the...
Marius Pharmaceuticals Announces Launch of ReThink Testosterone, Disease-State Awareness Initiative for Patients
24 juil. 2023 09h00 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., July 24, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or Testosterone Deficiency, is proud to...
Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome
20 juin 2023 08h30 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 20, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or testosterone deficiency, announced today...
Marius Pharmaceuticals Announces Two Key Patents Related to KYZATREX™ in FDA Orange Book
09 juin 2023 10h00 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 09, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on therapies designed for hypogonadism or testosterone deficiency, announced...
CORRECTION -- Marius Pharmaceuticals Receives FDA Approval of KYZATREX™, an Oral Testosterone Replacement Therapy
21 sept. 2022 11h08 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on August 2, 2022 by Marius Pharmaceuticals, please note that the correct number for reporting side...
Marius Announces Ambulatory Blood Pressure Results Published in the Journal of Clinical Hypertension with their new testosterone medication KYZATREX™
11 juin 2021 11h11 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 11, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focusing on therapies designed for hypogonadism, more commonly known as testosterone...
Marius Pharmaceuticals Receives PDUFA Date for KYZATREX® NDA for Treatment of Hypogonadism
11 mars 2021 10h00 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) goal...
Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX
28 janv. 2021 10h00 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone...